[go: up one dir, main page]

WO2004111090A3 - Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation - Google Patents

Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation Download PDF

Info

Publication number
WO2004111090A3
WO2004111090A3 PCT/FR2004/001435 FR2004001435W WO2004111090A3 WO 2004111090 A3 WO2004111090 A3 WO 2004111090A3 FR 2004001435 W FR2004001435 W FR 2004001435W WO 2004111090 A3 WO2004111090 A3 WO 2004111090A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
molecules
segment
therapeutic
therapeutic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2004/001435
Other languages
English (en)
Other versions
WO2004111090A2 (fr
Inventor
Francoise Russo-Marie
Alain Samson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIONEXIS
Original Assignee
BIONEXIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIONEXIS filed Critical BIONEXIS
Priority to EP04767301A priority Critical patent/EP1631592A2/fr
Priority to US10/560,025 priority patent/US20060154854A1/en
Priority to CA002528186A priority patent/CA2528186A1/fr
Publication of WO2004111090A2 publication Critical patent/WO2004111090A2/fr
Publication of WO2004111090A3 publication Critical patent/WO2004111090A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention se rapporte à des molécules chimères permettant le ciblage et la libération de composés thérapeutiques chez des mammifères, notamment des humains. Les molécules de l'invention comprennent principalement trois segments ou domaines fonctionnels : un segment de ciblage, capable de se lier préférentiellement à la surface des cellules ciblées, un segment thérapeutique, comprenant le composé biologiquement actif, et un segment de liaison entre le segment de ciblage et le segment thérapeutique, le segment de liaison étant clivable sur le site cible. L'invention concerne également la préparation de ces molécules, des intermédiaires de synthèse ou domaines de celles-ci, des compositions pharmaceutiques les contenant, et leurs utilisation, en particulier dans le domaine pharmaceutique. Les molécules et compositions de l'invention sont tout particulièrement adaptées au ciblage de cellules pathologiques engagées dans une voie apoptotique, et au traitement de pathologies ou tissus associés, notamment les cancers et l'inflammation.
PCT/FR2004/001435 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation Ceased WO2004111090A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04767301A EP1631592A2 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
US10/560,025 US20060154854A1 (en) 2003-06-10 2004-06-09 Molecules for targeting and releasing therapeutic compounds, and the use thereof
CA002528186A CA2528186A1 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0306944A FR2856069A1 (fr) 2003-06-10 2003-06-10 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
FR03/06944 2003-06-10

Publications (2)

Publication Number Publication Date
WO2004111090A2 WO2004111090A2 (fr) 2004-12-23
WO2004111090A3 true WO2004111090A3 (fr) 2005-09-09

Family

ID=33484306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/001435 Ceased WO2004111090A2 (fr) 2003-06-10 2004-06-09 Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation

Country Status (5)

Country Link
US (1) US20060154854A1 (fr)
EP (1) EP1631592A2 (fr)
CA (1) CA2528186A1 (fr)
FR (1) FR2856069A1 (fr)
WO (1) WO2004111090A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
EP2771030A4 (fr) * 2011-10-24 2015-07-22 Intellect Neurosciences Inc Compositions et méthodes de traitement de protéinopathies
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2017184683A1 (fr) * 2016-04-21 2017-10-26 The Board Of Regents Of The University Of Taxas System Méthodes et compositions permettant de détecter des anévrismes
EP3455628A4 (fr) * 2016-05-09 2019-12-04 Biodesy, Inc. Méthodes et dispositifs de détection d'interactions de protéines membranaires périphériques à l'aide de techniques optiques non linéaires
EP4482853A1 (fr) * 2022-02-23 2025-01-01 Resother Pharma A/S Analogues polypeptidiques dérivés de l'annexine a1

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009953A1 (fr) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Procedes permettant d'obtenir des proteines hybrides de fixation de phospholipides
WO1992019279A1 (fr) * 1991-05-09 1992-11-12 Board Of Regents Of The University Of Washington Agents thrombolytiques cibles sur des phospholipides
WO1999019470A2 (fr) * 1997-10-09 1999-04-22 The Regents Of The University Of California Proteines de fusion de la gfp et de l'annexine
WO1999060135A1 (fr) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation de produits geniques multiples a partir de proteines chimeres de fusion, par clivage a l'aide d'endoproteases ubiquistes
FR2784106A1 (fr) * 1998-10-02 2000-04-07 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
WO2003008594A1 (fr) * 2001-07-20 2003-01-30 Gene-Life Biotechnology (Shanghai) Limited Construction du plasmide pour l'expression de la proteine de fusion thrombolytique ciblant de thrombus
US20030059432A1 (en) * 2000-02-11 2003-03-27 Dillon Davin C. Lipophilin complexes for use in cancer diagnosis and therapy
WO2004003016A2 (fr) * 2002-07-01 2004-01-08 Commissariat A L'energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009953A1 (fr) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Procedes permettant d'obtenir des proteines hybrides de fixation de phospholipides
WO1992019279A1 (fr) * 1991-05-09 1992-11-12 Board Of Regents Of The University Of Washington Agents thrombolytiques cibles sur des phospholipides
WO1999019470A2 (fr) * 1997-10-09 1999-04-22 The Regents Of The University Of California Proteines de fusion de la gfp et de l'annexine
WO1999060135A1 (fr) * 1998-05-21 1999-11-25 Cancer Research Ventures Limited Generation de produits geniques multiples a partir de proteines chimeres de fusion, par clivage a l'aide d'endoproteases ubiquistes
FR2784106A1 (fr) * 1998-10-02 2000-04-07 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US20030059432A1 (en) * 2000-02-11 2003-03-27 Dillon Davin C. Lipophilin complexes for use in cancer diagnosis and therapy
WO2003008594A1 (fr) * 2001-07-20 2003-01-30 Gene-Life Biotechnology (Shanghai) Limited Construction du plasmide pour l'expression de la proteine de fusion thrombolytique ciblant de thrombus
WO2004003016A2 (fr) * 2002-07-01 2004-01-08 Commissariat A L'energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 1 October 1996 (1996-10-01), XP002269417, Database accession no. P09525 *

Also Published As

Publication number Publication date
EP1631592A2 (fr) 2006-03-08
US20060154854A1 (en) 2006-07-13
FR2856069A1 (fr) 2004-12-17
WO2004111090A2 (fr) 2004-12-23
CA2528186A1 (fr) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2007127474A3 (fr) Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
EP2535355A3 (fr) Anticorps diriges contre CD38 pour le traitement du myelome multiple
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases
WO2008063291A3 (fr) Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
WO2007093183A3 (fr) Procede de traitement de maladies inflammatoires
ATE330967T1 (de) An her2 bindende peptidverbindungen
WO2006007712A8 (fr) Methodes permettant de distribuer des agents therapeutiques comprenant des conjugues de lipide-polyethylene glycol
WO2008130320A3 (fr) Nouveaux composés 806
WO2007038209A3 (fr) Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL231077A0 (en) Pharmaceutical compositions comprising a pd-1 antagonist for treating infections and tumors
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
WO2007120729A3 (fr) Composés de pyridylamide antagonistes des canaux calciques de type t
WO2008085794A3 (fr) Méthodes et compositions associées à des composés adhérant aux caillots
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2009077741A3 (fr) Amides d'acides 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5-tétrazine-8-carboxyliques substitués en position 3 et leur utilisation
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
EP2004177A4 (fr) Composes de nitrofurane utilises dans le traitement du cancer et de l'angiogenese
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004767301

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2528186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006516277

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006154854

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10560025

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004767301

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10560025

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004767301

Country of ref document: EP